PBIO redesigned its UST Technology Platform to be
Post# of 15365
![Avatar](/images/ProfileImages/734810790_1098_wst.png)
The company's BaroShear K45 product launch couldn't have come at a more opportune time in the CBD industry's history. With the passage of the 2018 Farm Bill, entrepreneurs are rushing to grow hemp and extract CBD oil that is water soluble and safe for sale to individual consumers or as an ingredient that is infused into beverages. Projected revenue for CBD infused beverages alone is expected to be $220 million by 2022.
The company recently projected this years revenue to double from $2.5 million to $5 million as a result of the high demand expected for the company's BaroShear K45 technology. Technology companies with 100% growth rates can easily trade at upwards of 10 times annual sales which could realistically lead to a $50 million valuation for the company's stock. With less than 2 million shares outstanding the stock may move significantly higher from current levels in the near term as the current market capitalization is a miniscule $5.9 million offering a substantial upside to the company's shares. Trading at only 1.2 times this years forecasted sales PBIO is a very cheap stock compared with its CBD industry peers. The company previously traded on the NASDAQ for upwards of $18.00. The CBD market is hot and valuations are soaring. PBIO is a great way to add the extraordinary growth of the CBD sector to your portfolio.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)